Despite the slow trickle of updates on President Donald Trump’s proposed pharmaceutical import tariffs, drugmakers have continued to make U.S. manufacturing pledges throughout the year. Now, India’s ...

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

For $45 million upfront, Vor Bio is gaining ex-China rights to RemeGen’s telitacicept, a first-in-class recombinant ...

In a breakthrough for incretin medicines, China’s National Medical Products Administration (NMPA) has approved Innovent’s ...

While the first meeting of Robert F. Kennedy Jr.’s reshuffled Advisory Committee on Immunization Practices didn’t yield any ...

Restricted availability under an FDA-mandated drug safety program has limited the reach of CAR-T cell therapies for certain ...

UCB’s Fintepla has been approved to treat seizures associated with two epilepsy disorders and now has posted data that could ...

The medtech this week launched a podcast called “Decoded,” in which founder and CEO Jurgi Camblong, Ph.D., will host expert ...

After blueprinting an injectables facility in North Carolina in 2020, it didn’t take long for Eli Lilly to draw up designs ...

The CDC’s Advisory Committee on Immunization Practices (ACIP) has blessed Merck’s new respiratory syncytial virus (RSV) shot ...

After over a decade spent building Incyte up into a competitive commercial drugmaker, the company’s longtime CEO Hervé ...

A potential $4 billion licensing deal with Vor Bio triggered a slide in RemeGen's stock price. Otsuka obtained a BCMAXCD3 ...